ClinicalTrials.gg
DrugBiological

Siplizumab clinical trials

Also written MEDI-507 and TCD601.

studies test it
26
open now
4
in phase 3
0
first study started
1997

How each study uses siplizumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the siplizumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Siplizumab
12

Development codes

MEDI-507
12
TCD601
10

Studies by the year they started

26 studies that test it; most in 2023 (6)

Studies that test siplizumab, by start year
YearStudies
19971
19981
19992
20012
20021
20041
20051
20081
20091
20131
20212
20222
20236
20242
20251
20261

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
13
Phase 2
16

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 17 · Other 9

ITB-Med LLC (9) · MedImmune LLC (8) · Massachusetts General Hospital (3) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · National Cancer Institute (NCI) (1) · University of Alabama at Birmingham (1) · Elizabeth C. Verna (1) · Columbia University (1)

Often tested with

Tested in the same studies.

Rituximab (2) · Fludarabine (1) · Cyclophosphamide (1)

Studies

Open first, then newest update. How each study uses siplizumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 26

See all 26 studies that test siplizumab →

What changed recently

From the registry's own updates since Oct 18, 2026.

Codes

What other systems call siplizumab · ClinicalTrials.gg INT005505

  • MeSH (NLM) C544394siplizumabConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) KUW1QG1ZM3SIPLIZUMABConfirmed FDA, NLM, Wikidata
  • Wikidata Q7525805SiplizumabConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C38685SiplizumabOne source FDA
  • DrugBank DB06371One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.